Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

Now Viewing

EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer

EP: 3.HER2+ Breast Cancer: Anthracycline Considerations

EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends

EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer

EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer

EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer

EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights

EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges

EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

In this oncology discussion led by O’Shaughnessy, experts explore recent data updates shaping clinical practices for patients with HER2-positive breast cancer. The panel discusses the significance of neoadjuvant treatment, emphasizing goals such as achieving a pathologic complete response and tailoring strategies based on disease burden, hormone receptor status, and genomic predictors. Pertuzumab’s role is scrutinized, and the impact of a patient’s age on long-term prognosis is assessed. The dialogue offers insights into evolving management practices, incorporating recent trial data to refine HER2-positive breast cancer care. It serves as a valuable resource for health care professionals navigating the latest advancements and challenges in this field.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.